Nesfrotamig

内斯弗妥米单抗

Report date: 2026/03/26 20:00:17

Base Information

Drug NameNesfrotamig

Drug Alias NameABL105YH-32367

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-HER2Anti-Tumor necrosis factor receptor superfamily member 9

TargetsReceptor protein-tyrosine kinase erbB-2Tumor necrosis factor receptor superfamily member 9

Therapy Area/IndicationsSolid tumoursStomach NeoplasmsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustraliaSouth Korea

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAbl Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesAbl Bio Inc Yuhan Corp

Inactive CompaniesN/A

Active IndicationsSolid tumoursStomach NeoplasmsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A